Table 6.

Net 5-year budget impact of increasing abobotulinumtoxinA market share compared to status quo assumptions in the treatment of cervical dystonia in the UK

	Year 1 (£)	Year 2 (£)	Year 3 (£)	Year 4 (£)	Year 5 (£)	Total (£)
Budget under status quo assumptions	19,991,484	20,193,298	20,397,149	20,603,059	20,811,047	101,996,037
Budget under new market share assumptions	19,991,484	19,972,687	19,951,473	19,927,795	19,901,606	99,745,045
Net budget impact	0	–220,611	–445,677	–675,264	–909,441	–2,250,992